AdvanCell Revenue and Competitors

Sydney, AUS

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AdvanCell's estimated annual revenue is currently $9.5M per year.(i)
  • AdvanCell's estimated revenue per employee is $155,000

Employee Data

  • AdvanCell has 61 Employees.(i)
  • AdvanCell grew their employee count by 74% last year.

AdvanCell's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Commercial Officer & Chief Operating OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Nuclear Scientist (Consulting)Reveal Email/Phone
5
VP, Regulatory Affairs & Late-Stage DevelopmentReveal Email/Phone
6
Head Quality and Regulatory AffairsReveal Email/Phone
7
VP DiscoveryReveal Email/Phone
8
Director EngineeringReveal Email/Phone
9
Director Preclinical ScienceReveal Email/Phone
10
Associate Director Preclinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$63.9M41228%N/AN/A
#2
$16.9M1099%N/AN/A
#3
$22.6M14621%N/AN/A
#4
$18.1M1176%N/AN/A
#5
$392M25294%N/AN/A
#6
$66.8M43139%N/AN/A
#7
$18.8M12127%N/AN/A
#8
$16.6M107-14%N/AN/A
#9
$2M1386%N/AN/A
#10
$18.3M11818%N/AN/A
Add Company

What Is AdvanCell?

AdvanCell is a radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au

keywords:N/A

N/A

Total Funding

61

Number of Employees

$9.5M

Revenue (est)

74%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.9M6117%N/A
#2
$17.7M6127%N/A
#3
$13.9M619%N/A
#4
$15.3M6133%N/A
#5
$8.8M61-2%N/A